Hong Kong-listed Shanghai Henlius Biotech surged by the most since it floated its shares five years ago after drug maker Fosun Pharma offered HK$5.4 billion (US$690 million) to privatise the company. Fosun Pharma, the pharmaceutical arm of the sprawling Chinese conglomerate Fosun International, […]